Health Canada Authorizes PiaSky® (crovalimab for injection) As the First Monthly (Every Four Weeks) Subcutaneous Treatment for People With Paroxysmal Nocturnal Hemoglobinuria (PNH) Français
PiaSky® (crovalimab for injection) has the potential to help reduce treatment burden for people with PNH in Canada and their caregivers (2, 3)
MISSISSAUGA, ON, June 11, 2025 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that Health Canada has authorized PiaSky® (crovalimab for injection) as the first monthly (every four weeks) subcutaneous therapy indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults and adolescents 13 years of age and older with a body weight of at least 40 kg. (1)
"We are pleased to offer PiaSky as a new option to the treatment landscape for Canadians living with PNH," said Brigitte Nolet, President and CEO, Roche Pharma Canada. "With a self-administration option available for appropriate patients, as determined by their doctor, individuals can choose to treat their disease at home without requiring IV access, and feel empowered to take an active role in their own care. This flexibility of administration may help reduce treatment burden for patients, their caregivers, and healthcare systems, and is part of Roche's ongoing commitment to bringing Canadians new therapies that have a broader value to society."
PNH is a rare, genetically acquired, and life-threatening disease of the bone marrow where red blood cells deficient in certain protective markers are destroyed by the complement system, which helps defend against infection. (4) The destruction of these abnormal blood cells lead to symptoms such as anemia, fatigue, hemoglobinuria (blood in the urine), and blood clots. (5, 6) Globally, the estimated prevalence of PNH is estimated at 15.9 cases per million, affecting fewer than 1,000 individuals in Canada. (7) Complement component 5 (C5) inhibitors – treatments that block part of the complement system cascade – have been shown to be effective in treating PNH. (4, 5, 6, 8)
"The approval of crovalimab, a novel C5 inhibitor, provides further freedom of choice for patients with PNH receiving terminal complement blockade," said Dr. Christopher Patriquin, Chair of the Canadian PNH Network and Assistant Professor of Medicine and Clinician Investigator at the University of Toronto. "Blocking C5 directly was the first approved strategy for treating such patients, and this new drug will allow them another option. They can now choose to get the disease-controlling treatment in small-volume, subcutaneous doses every 4 weeks, and even, in appropriate cases, self-administer them, instead of the other available C5 inhibitors which are given intravenously."
"Monthly (every four weeks) self-injection of crovalimab has the potential to improve the quality of life for people living with PNH," said Barry Katsoff, President, Canadian Association of PNH Patients. "The potential for a more manageable, home-administered solution is especially meaningful for PNH patients whose daily lives are often disrupted by the demands of ongoing therapy. Canadian patients welcome the introduction of crovalimab to our basket of options."
Health Canada's authorization of PiaSky is based on the pivotal COMMODORE 2 Phase III study in people with PNH who have not previously been treated with C5 inhibitors. (1, 9, 10) The study demonstrated that PiaSky, administered as subcutaneous (SC) injections every four weeks, achieved disease control (as measured by hemolysis control and transfusion avoidance) and was well-tolerated. (1)
Roche Canada is committed to working with the provincial and territorial jurisdictions to make PiaSky available as soon as possible through public and private drug plans for the patients who need it.
About paroxysmal nocturnal hemoglobinuria (PNH)
PNH is a rare hematological disease that may develop on its own or in the context of other bone marrow disorders such as aplastic anemia. Somatic mutations to the PIGA gene lead to clonal expansion of hematopoietic stem cells in the bone marrow which lack certain protein cell surface markers. The absence of these markers renders blood cells susceptible to lysis by the complement system, part of our innate immune defense against common pathogens. These processes cause anemia, thrombosis (blood clots), fatigue, and other debilitating symptoms that significantly impact quality of life and mental health. Individuals can be diagnosed at any stage of life, but are most commonly diagnosed in their 30's or 40's. (5, 6, 11, 12)
About PiaSky ® [crovalimab for injection]
PiaSky is a novel recycling monoclonal antibody that inhibits the complement protein C5 and is designed to block the complement system. (1, 10) It is recycled within the bloodstream, allowing the medicine to bind and inhibit the C5 protein multiple times and to act longer in the body with a small volume of medicine. (1, 13) Individuals will have the option to self-administer PiaSky following an initial intravenous (IV) infusion and weekly subcutaneous (SC) loading doses in the first month of treatment, in appropriate cases following adequate training. (1) PiaSky's flexibility of administration may help to reduce treatment burden and disruption to the lives of people with PNH and their caregivers. (2, 3)
About the COMMODORE 2 study
The COMMODORE 2 study is a Phase III, randomised, open-label study evaluating the efficacy and safety of PiaSky® (crovalimab for injection) versus eculizumab in people with paroxysmal nocturnal hemoglobinuria who have not been treated previously with C5 inhibitors. The study's co-primary efficacy endpoints measure transfusion avoidance and control of hemolysis (the ongoing destruction of red blood cells measured by lactate dehydrogenase levels). The adults enrolled in the study were randomised in a 2:1 ratio to be treated with either subcutaneous (SC) PiaSky every four weeks or intravenous eculizumab every two weeks. The participants who were less than 18 years old were included in a non-randomised treatment arm and were treated with SC PiaSky every four weeks. (9, 10)
About Roche Canada
At Roche Canada, patients and science are at the heart of everything we do. Our passion for science and our commitment to relentlessly pursuing the impossible for patients have made us one of the world's leading pharmaceutical, in-vitro diagnostics, and diabetes care management companies.
With our combined strength in diagnostics and pharmaceuticals, we're driving healthcare forward, while ensuring we deliver meaningful benefits for patients and a sustainable healthcare system. Because we're committed to making quality healthcare accessible to everyone.
And we're adding our expertise in new areas, such as artificial intelligence, real world data collection and analysis and collaborating with many different sectors and industries.
Having the courage to reinvent ourselves and question the status quo is what patients and the healthcare system expect from Roche - and our commitment is as strong today as it was on the first day of our Canadian journey in 1931. Today, Roche Canada employs more than 1,800 people across the country through its Pharmaceuticals division in Mississauga, Ontario as well as its Diagnostics and Diabetes Care divisions in Laval, Quebec.
PiaSky Product Monograph, June 4, 2025
Roth A, Nishimura JI, Nagy Z, Gaal-Weisinger J, Panse J, Yoon SS, et al. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood. 2020;135(12):912–20.
Sampei Z, Haraya K, Gan SW, Muraoka M, Hayasaka A, Fukuzawa T, et al. Beyond Recycling Antibodies: Crovalimab's Molecular Design Enables Four-Weekly Subcutaneous Injections for PNH Treatment. Int J Mol Sci. 2024;25(21).
Shah N, Bhatt H. Paroxysmal nocturnal hemoglobinuria. StatPearls. Treasure Island (FL) 2022.
Schrezenmeier H, Roth A, Araten DJ, Kanakura Y, Larratt L, Shammo JM, et al. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry. Ann Hematol. 2020;99(7):1505–14.
Patriquin CJ, Kiss T, Caplan S, Chin-Yee I, Grewal K, Grossman J, et al. How we treat paroxysmal nocturnal hemoglobinuria: a consensus statement of the Canadian PNH Network and review of the national registry. Eur J Haematol. 2019;102(1):36–52.
Hill A, Platts PJ, Smith A, Richards SJ, Cullen MJ, Hill QA, et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire. Blood. 2006;108:985.
Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233–43.
COMMODORE 2 (NCT04434092). [Internet; cited June 2025] Available at: https://www.clinicaltrials.gov/ct2/show/NCT04434092.
Roth A, He G, Tong H, Lin Z, Wang X, Chai-Adisaksopha C, et al. Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition. Am J Hematol. 2024;99(9):1768-77.
Oliver MP, C. Paroxysmal Nocturnal Hemoglobinuria: Current Management, Unmet Needs, and Recommendations. J Blood Med. 2023:613-28.
Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106(12):3699–709.
Fukuzawa T, et al. Long lasting neutralisation of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. Sci Rep. 2017;7(1):1080.
SOURCE Hoffmann-La Roche Limited (Roche Canada)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
4 hours ago
- Cision Canada
Health Canada Approves Dual Immunotherapy OPDIVO® Plus YERVOY® for Colorectal and Liver Cancers Français
MONTREAL, Aug. 19, 2025 /CNW/ - Bristol Myers Squibb Canada (BMS) today announced that Health Canada has approved OPDIVO ® (nivolumab) in combination with YERVOY ® (ipilimumab) for the first-line treatment of adult patients with: unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), and unresectable or advanced hepatocellular carcinoma (HCC) 1. This dual immunotherapy regimen offers a new first-line treatment approach for two challenging gastrointestinal cancers, supported by two pivotal Phase 3 trials: CheckMate-8HW in CRC which demonstrated improvement in progression-free survival, and CheckMate-9DW in HCC which showed improvements in survival—each compared to existing standard therapies 1. "Although we've seen progress, microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer is clinically complex, particularly in the first-line setting where there remains an ongoing need for additional treatments," said Vancouver-based medical oncologist, Dr. Sharlene Gill. "The approval of OPDIVO ® plus YERVOY ®, supported by CheckMate-8HW, the largest phase 3 immunotherapy trial to date in this population, offers a well-studied and very clinically meaningful option for patients and clinicians treating this distinct molecular subtype of colorectal cancer." Calgary-based medical oncologist, Dr. Hatim Karachiwala added,"For patients with unresectable or advanced hepatocellular carcinoma improving outcomes continues to be a critical priority. Data from CheckMate-9DW provides useful insights into how the OPDIVO ® plus YERVOY ® dual immunotherapy strategy might be considered as part of the initial treatment approach." BMS introduced immunotherapy in Canada in 2012 with the approval of YERVOY ®, ushering in a new era of cancer treatment providing an important option for patients with advanced cancers. The 2016 approval of the first dual immunotherapy regimen—YERVOY ® plus OPDIVO ® —further expanded this foundation. These latest indications further expand the reach of the combination to include MSI-H/dMMR colorectal and liver cancer patients. Immunotherapy Advances Welcomed by Patient Groups "In a country where colorectal cancer remains one of the most commonly diagnosed cancers and a leading cause of cancer death for both men and women 2, this news represents a much-needed advancement," said Barry Dr. Stein, President and CEO, Colorectal Cancer Canada. "This dual immunotherapy approach provides eligible patients and their care teams with a new, clinically validated strategy to take action early in the treatment journey." Filomena Servidio-Italiano, President and CEO, Colorectal Cancer Resource & Action Network (CCRAN), added, "These approvals mark important progress for both the colorectal and liver cancer communities. For those facing aggressive disease, time matters. Expanding access to first-line immunotherapy—particularly with combination strategies that enhance the immune system engagement—responds to an important unmet need." "Making up approximately 75% all primary liver cancer cases 3, hepatocellular carcinoma has a significant impact on patients across the country," said Jennifer Nebesky, President and CEO, Liver Canada. "In 2024, liver cancer was projected to be diagnosed in 4,700 Canadians, with 3,700 deaths 4 —figures that speak to the need for continued progress in improving care. The approval of OPDIVO ® plus YERVOY ® as a first-line treatment provides renewed hope and a new path forward for patients and clinicians alike." In the CheckMake-8HW trial, OPDIVO ® plus YERVOY ® reduced the risk of disease progression or death by 79% compared to chemotherapy in the first-line treatment of MSI-H/dMMR metastatic colorectal cancer. In advanced hepatocellular carcinoma, the CheckMate-9DW trial showed the combination delivered a statistically significant overall survival benefit compared to tyrosine kinase inhibitors. These results highlight the potential of dual immunotherapy to drive meaningful change in early treatment across both cancers. "These approvals underscore our continued focus on advancing immunotherapy where it can make a meaningful difference," said Elaine Phillips, General Manager, Bristol Myers Squibb Canada. "By introducing OPDIVO ® plus YERVOY ® as a first-line treatment option for these two distinct and challenging gastrointestinal cancers, we are expanding access to a dual immunotherapy approach in areas with significant unmet need. This milestone reflects our commitment to delivering innovative science with real-world impact." Clinical Trials Overview OPDIVO ® (nivolumab), in combination with YERVOY ® (ipilimumab), was evaluated in two pivotal Phase 3 trials—CheckMate-8HW and CheckMate-9DW—supporting its first-line use in MSI-H/dMMR colorectal and liver cancers. CheckMate-8HW is a global, randomized, open-label Phase 3 trial that enrolled 839 patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC). The trial included an evaluation of OPDIVO ® plus YERVOY ® (n=202) versus standard-of-care chemotherapy (with or without bevacizumab or cetuximab) (n=101). The OPDIVO ® plus YERVOY ® versus investigator's choice chemotherapy with/without bevacizumab or cetuximab arm of the trial showed that the combination regimen reduced the risk of cancer progression or death by 79% compared to chemotherapy in centrally confirmed MSI-H/dMMR mCRC first-line patients (HR 0.21; 95% CI: 0.14-0.32; P<0.0001). After a median follow-up of 31.5 months, median progression-free survival (PFS) was not reached with OPDIVO ® plus YERVOY ® (95% CI: 38.4-NE) compared to 5.9 months with chemotherapy (95% CI: 4.4-7.8). Kaplan-Meier curves showed early and sustained separation starting at three months, with PFS rates of 79% vs. 21% at 12 months and 72% vs. 14% at 24 months, respectively. CheckMate-9DW is a global, randomized, open-label Phase 3 trial that enrolled 668 patients with unresectable or advanced hepatocellular carcinoma (HCC) who had not received prior systemic therapy. Patients were randomized to receive OPDIVO ® plus YERVOY ® (n=335) or investigator's choice of lenvatinib or sorafenib monotherapy (n = 333). The dual immunotherapy regimen consisted of OPDIVO ® 1 mg/kg plus YERVOY ® 3 mg/kg every three weeks for up to four doses, followed by OPDIVO ® monotherapy 480 mg every four weeks. The trial demonstrated a statistically significant improvement in overall survival (OS): median OS was 23.7 months with OPDIVO ® plus YERVOY ® versus 20.6 months with lenvatinib/sorafenib (HR 0.79; 95% CI: 0.65–0.96; p = 0.0180). The overall response rate (ORR) was 36.1% vs. 13.2% (p < 0.0001), with complete responses in 6.9% of patients receiving dual immunotherapy. Median duration of response was 30.4 months vs.12.9 months. In both trials, the safety profile of OPDIVO ® plus YERVOY ® was consistent with the known class effects of PD-1 and CTLA-4 inhibitors. Immune-mediated adverse events were generally manageable with established treatment algorithms. For more information, including prescribing and safety information related to the new indications, please consult the Canadian product monograph for OPDIVO ® here. About Bristol Myers Squibb Canada Co. Bristol Myers Squibb Canada Co. is an indirect wholly-owned subsidiary of Bristol Myers Squibb Company, a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Bristol Myers Squibb Canada Co. employs close to 300 people across the country. For more information, please visit ____________ SOURCE Bristol-Myers Squibb Canada
Cision Canada
4 hours ago
- Cision Canada
Cepheid Receives Health Canada Licence for Xpert® HCV VL Fingerstick
Detection and quantitation of Hepatitis C virus (HCV) in about an hour SUNNYVALE, Calif. , Aug. 19, 2025 /CNW/ -- Cepheid today announced that Health Canada has issued Cepheid a medical device licence for Xpert ® HCV VL Fingerstick, an HCV RNA test that detects and quantifies HCV directly from a drop of blood, simplifying the diagnostic pathways to speed up linkage to care and monitoring sustained virological response. Xpert HCV VL Fingerstick test is performed on the GeneXpert ® system. There is no vaccine for hepatitis C, but it can be treated and cured with antiviral medications. The Health Infobase estimates that over 200,000 people are living with chronic hepatitis C in Canada. 1 Globally, more than half of people with HCV do not know that they have the virus. "Timely diagnosis is key to identifying and treating people with hepatitis C. Point-of-care tests allow us to diagnose people wherever they are, without necessarily needing them to come to traditional health care facilities. This can be hugely impactful, particularly for those who do not have equitable access to health care, such as people who use drugs and people in remote settings," said Dr. Jordan Feld, Director of the Toronto Centre for Liver Disease and Professor of Medicine at the University of Toronto. "To reach the World Health Organization's goal of eliminating HCV by 2030, we need to find and diagnose those living with HCV and get them access to care and treatment. Point-of-care tests make that much more feasible." "This simple to use test detects the full range of known HCV genotypes in about an hour and can be performed on a small volume of blood collected via fingerstick," said Vitor Rocha, President of Cepheid. "This is the first HCV RNA detection and quantification technology sensitive enough for active case finding at the point of care in Canada. This enables diagnosis of HCV and facilitates timely linkage to care within a single clinic visit — and with this, the potential for treating more people with HCV." The test is designed for use on Cepheid's GeneXpert system which provides simple, reference lab quality PCR testing on location in laboratory environments at medical centers and hospitals or in community health clinics and physician offices. Xpert® HCV VL Fingerstick will begin shipping to customers in Canada in August 2025. Visit for more information. 1. Accessed July 2025 About Cepheid Based in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is an operating company within Danaher Corporation's Diagnostics platform. Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit IVD. In Vitro Diagnostic Medical Device. May not be available in all countries For Cepheid Media Inquiries: Darwa Peterson [email protected]
Cision Canada
4 hours ago
- Cision Canada
Health Canada approves Ozempic® to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease Français
Ozempic ® is the first-and-only medication indicated for both the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control and to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. 1 Chronic kidney disease in patients with type 2 diabetes is associated with an elevated risk of end-stage kidney disease, cardiovascular disease, and death. 2 MISSISSAUGA, ON, Aug. 19, 2025 /CNW/ - Novo Nordisk announced today that Ozempic ® (semaglutide injection) is now approved as the first-and-only medication indicated for both the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control and to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD). 1 Dr. David Cherney, Senior Scientist, Toronto General Hospital Research Institute, and Primary Investigator on FLOW, says: "Chronic kidney disease, or CKD, affects 30-50% of people living with type 2 diabetes (T2D), and is associated with a dramatically higher risk of cardiovascular disease and mortality. Fortunately, we have witnessed a significant evolution in the management of CKD in T2D over the last 5 years with the identification of newer therapies that reduce both heart and kidney risk in T2D. The results of the FLOW trial are of major importance for people living with type 2 diabetes and chronic kidney disease because this trial demonstrated that the addition of semaglutide to standard of care medicines reduced the risk of kidney disease progression, and death due to cardiovascular disease or loss of kidney function over time. Based on the FLOW results, we now can offer our patients a better chance of avoiding kidney failure or cardiovascular complications." Dr. Alice Cheng, Endocrinologist at Trillium Health Partners and Unity Health Toronto, and Associate Professor at University of Toronto, says: "Many people living with type 2 diabetes may not be aware that they have chronic kidney disease (CKD) which is why it is so important to ensure that a urine test is done at least annually. The FLOW study provides evidence that there is another tool in the toolbox to not only slow the progression of kidney disease but also reduce cardiovascular risk in people living with type 2 diabetes and CKD - a tool that is already familiar to us. The more tools, the better." Health Canada's CKD indication for Ozempic ® is based on the results of the FLOW trial. The dedicated kidney outcomes trial was designed to determine the kidney-protective effects of semaglutide in participants with CKD and T2D, as well as assessing the effect of CVD mortality. The FLOW trial achieved its primary endpoint, with semaglutide 1 mg demonstrating a 24% reduction in the risk of kidney disease progression and cardiovascular and kidney mortality compared to placebo (331 vs. 410 events; hazard ratio: 0.76 [0.66; 0.88]; P=0.0003). 3 About the FLOW Trial FLOW was an international, randomized, double-blind, parallel-group, placebo-controlled, event-driven superiority trial comparing injectable semaglutide 1 mg with placebo as an adjunct to standard of care on kidney outcomes for reducing the risk of progression of kidney impairment and risk of kidney and cardiovascular mortality in people with type 2 diabetes and CKD (defined as eGFR 2 ≥50 and ≤75mL/min/1.73 m 2 and UACR >300 and <5000 mg/g or eGFR ≥25 and <50 mL/min/1.73 m 2 and UACR >100 and <5000 mg/g). 3,533 people (1,767 in the semaglutide group and 1,766 in the placebo group) were enrolled in the trial conducted in 28 countries, including Canada, at around 400 investigator sites. The FLOW trial was initiated in 2019, 1 and was stopped early due to efficacy, based on a recommendation from an Independent Data Monitoring Committee. The key objective of the FLOW trial was to demonstrate delay in the progression of CKD and a lower risk of kidney and cardiovascular mortality through the composite primary endpoint consisting of the following five components: onset of persistent ≥ 50% reduction in eGFR according to the CKD-EPI 3 equation compared with baseline, onset of persistent eGFR (CKD-EPI) < 15 mL/min/1.73 m 2, initiation of chronic kidney replacement therapy (dialysis or kidney transplantation), death from kidney disease or death from cardiovascular disease. Confirmatory secondary endpoints included annual rate of change in eGFR (CKD-EPI), MACE (non-fatal myocardial infarction, non-fatal stroke, cardiovascular death) and all-cause death. 1 About CKD and T2D CKD is a major health problem affecting approximately 4 million Canadians. 4 It is defined as the presence of kidney damage, or a decreased level of kidney function, for a period of three months or more. It can often start slow and develop without symptoms over a number of years and may not be detected until it has progressed to the point where kidney function is low. Kidney disease can be a devastating complication, as it is associated with significant reductions in both length and quality of life. 5 Around 40% of people with type 2 diabetes (T2D) will develop chronic kidney disease (CKD), 6 however, CKD is asymptomatic in its early stages and is under-diagnosed in people with T2D. 7 Renal function decline increases the probability of multi-morbidity as well as excess mortality. 8 T2D, CKD and cardiovascular disease (CVD) are interconnected. 9 About Ozempic Ozempic ® is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control. It was approved by Health Canada in 2018. Ozempic ® can be used with metformin, sulfonylurea and a sodium-glucose cotransporter 2 inhibitor (SGLT2i) and basal insulin with metformin. Ozempic ® is also indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. 10 For information about Ozempic ®, including important safety information, please view the product monograph here. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. ________________________________ 1 Novo Nordisk Canada Inc. (August 13, 2025). Ozempic ® Product Monograph. 2 Chu L, Fuller M, Jervis K, Ciaccia A, Abitbol A. Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study. Clin Ther. 2021 Sep;43(9):1558-1573. doi: 10.1016/ Epub 2021 Aug 21. PMID: 34426012. 3 Perkovic V, Tuttle KR, Rossing P, et al.. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. New England Journal of Medicine. 2024. 4 Kitzler TM, Chun J. Understanding the Current Landscape of Kidney Disease in Canada to Advance Precision Medicine Guided Personalized Care. Can J Kidney Health Dis. 2023 Feb 13;10:20543581231154185. doi: 10.1177/20543581231154185. PMID: 36798634; PMCID: PMC9926383. 5 Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018;42(Suppl 1):S1-S325. 6 Fenta ET, Eshetu HB, Kebede N, Bogale EK, Zewdie A, Kassie TD, Anagaw TF, Mazengia EM, Gelaw SS. Prevalence and predictors of chronic kidney disease among type 2 diabetic patients worldwide, systematic review and meta-analysis. Diabetol Metab Syndr. 2023 Nov 28;15(1):245. doi: 10.1186/s13098-023-01202-x. PMID: 38012781; PMCID: PMC10683270. 7 Dagogo-Jack S. Screening, Monitoring, Prevention, and Treatment Strategies for Chronic Kidney Disease in Patients with Type 2 Diabetes. 2021 Jun. In: Chronic Kidney Disease and Type 2 Diabetes. Arlington (VA): American Diabetes Association; 2021 Jun. Available from: doi: 10.2337/db20211-23 8 Perazella MA, Khan S. Increased mortality in chronic kidney disease: a call to action. Am J Med Sci. 2006 Mar;331(3):150-3. doi: 10.1097/00000441-200603000-00007. PMID: 16538076. 9 Usman MS, Khan MS, Butler J. The Interplay Between Diabetes, Cardiovascular Disease, and Kidney Disease. In: Chronic Kidney Disease and Type 2 Diabetes. Arlington (VA): American Diabetes Association; 2021 Jun. Available from: doi: 10.2337/db20211-13 10 Novo Nordisk Canada Inc. (August 13, 2025). Ozempic ® Product Monograph. SOURCE Novo Nordisk Canada Inc.
